Rite Aid Surges After Sales Forecast Tops Estimates

Rite Aid (RAD) Corp. rose to its highest value in a dozen years after the third-largest U.S. drugstore company provided a full-year sales forecast higher than analysts’ estimates.

Rite Aid gained 11 percent to $7.12 at 11:14 a.m. New York time after increasing to $7.39, its highest intraday price since Oct. 2, 2001. The shares of the Camp Hill, Pennsylvania-based company more than tripled in the 12 months through yesterday.

Revenue for fiscal 2015 is expected to be $26 billion to $26.5 billion, Rite Aid said in a statement today. That was more than analysts’ average estimate of $25.8 billion. Sales for the fourth quarter ended Feb. 28 were $6.6 billion, also higher than estimates.

Rite Aid is now positioned “to transition our strategy from turnaround to growth as we more aggressively pursue opportunities to become a growing retail health-care company,” Chief Executive Officer John Standley said in the statement.

To contact the reporter on this story: Anna Edney in Washington at aedney@bloomberg.net

To contact the editors responsible for this story: Reg Gale at rgale5@bloomberg.net Bruce Rule, Robert Valpuesta

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.